caa a22 4500 445338202 CHVBK 20180317142803.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1245/s10434-010-1191-0 doi (NATIONALLICENCE)springer-10.1245/s10434-010-1191-0 Serum Midkine Correlates with Tumor Progression and Imatinib Response in Gastrointestinal Stromal Tumors [Elektronische Daten] [Tamina Rawnaq, Miriam Kunkel, Kai Bachmann, Ronald Simon, Hilke Zander, Stephan Brandl, Guido Sauter, Jakob Izbicki, Jussuf Kaifi] Background: A previous study identified midkine (MK) expression in primary gastrointestinal stromal tumor (GIST) as a prognostic marker. The aim of the current study was to compare serum midkine (S-MK) concentrations of GIST patients with those of healthy controls and to determine if MK can serve as a prognostic serum marker for these patients. Materials and Methods: S-MK concentrations were measured by enzyme-linked immunosorbent assay in GIST patients (n=96) and healthy controls (n=148). S-MK levels were then correlated with clinicopathological data and the administration of imatinib therapy. In addition, MK expression was evaluated in 39 surgically resected GIST and in 17 leiomyoma specimens on a tissue microarray. Results: S-MK concentrations in GIST patients were significantly higher than in healthy controls: median (25th and 75th percentiles) S-MK concentration was 235 (139 and 376) pg/ml in the GIST patients and 99 (33 and 198) pg/ml in the controls (P<0.001; Mann-Whitney U test). Significantly higher median S-MK concentrations were found in GIST with recurrence compared with those without (295 vs 230; P=0.009). GIST patients with S-MK levels higher than 400pg/ml showed a significantly worse recurrence-free survival (P=0.026; log-rank test). Patients receiving imatinib therapy had decreased median S-MK concentrations compared with those who were not treated with imatinib (331 vs 201; P<0.001). Conclusions: S-MK concentration is a potential marker for evaluating the progression and prognosis of GIST, especially during imatinib therapy. Further studies could focus on the role of midkine in the tumorigenesis of GIST and responsiveness toward imatinib therapy. Society of Surgical Oncology, 2010 Rawnaq Tamina Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Kunkel Miriam Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Bachmann Kai Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Simon Ronald Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Zander Hilke Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Brandl Stephan Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Sauter Guido Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Izbicki Jakob Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Kaifi Jussuf Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 559-565 1068-9265 18:2<559 2011 18 10434 https://doi.org/10.1245/s10434-010-1191-0 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-010-1191-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Rawnaq Tamina Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Kunkel Miriam Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Bachmann Kai Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Simon Ronald Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Zander Hilke Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Brandl Stephan Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Sauter Guido Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Izbicki Jakob Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 700 1- Kaifi Jussuf Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/2(2011-02-01), 559-565 1068-9265 18:2<559 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer